| Recruiting | A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization Wi NCT07379580 | BioNTech SE | Phase 2 |
| Recruiting | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses. NCT07377175 | China National Biotec Group Company Limited | Phase 1 |
| Completed | A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared NCT05995275 | ModernaTX, Inc. | Phase 1 / Phase 2 |
| Completed | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults NCT05935917 | Emergent BioSolutions | Phase 1 |
| Completed | Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders NCT04485039 | SIGA Technologies | Phase 4 |
| Active Not Recruiting | Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS NCT04957485 | SIGA Technologies | Phase 2 |
| Completed | Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days NCT04971109 | SIGA Technologies | Phase 3 |
| Completed | Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years NCT05846243 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Phase 2 / Phase 3 |
| Completed | Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years NCT05976100 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Phase 1 |
| Withdrawn | A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox NCT03972111 | SIGA Technologies | — |
| Completed | Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG NCT04392739 | SIGA Technologies | Phase 4 |
| Completed | Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial NCT03699124 | Bavarian Nordic | Phase 3 |
| Completed | Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years NCT05762523 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Phase 1 |
| Completed | A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirima NCT02474589 | SIGA Technologies | Phase 3 |
| Completed | Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Im NCT02038881 | Bavarian Nordic | Phase 2 |
| Completed | Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE® NCT01827371 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vacc NCT01668537 | Bavarian Nordic | Phase 2 |
| Completed | A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smal NCT01144637 | Bavarian Nordic | Phase 3 |
| Completed | Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers NCT01317238 | Seoul National University Hospital | Phase 3 |
| Completed | Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and NCT00914732 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers NCT01056770 | Seoul National University Hospital | Phase 3 |
| Completed | Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel NCT01540929 | Emergent BioSolutions | — |
| Completed | A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year NCT00857493 | Bavarian Nordic | Phase 2 |
| Completed | High Dose IMVAMUNE® in Vaccinia-Naive Individuals NCT00879762 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Safety Surveillance Study of ACAM2000® Vaccinia Vaccine NCT00927719 | Emergent BioSolutions | — |
| Completed | Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®) NCT00928577 | Emergent BioSolutions | — |
| Completed | An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Tw NCT00686582 | Bavarian Nordic | Phase 2 |
| Completed | Phase I Trial of an Investigational Small Pox Medication NCT00728689 | SIGA Technologies | Phase 1 |
| Completed | Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study NCT00646152 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Safety and Efficacy of CJ-50300 in Healthy Volunteers NCT00607243 | Seoul National University Hospital | Phase 2 / Phase 3 |
| Completed | MVA Post-Event: Administration Timing and Boost Study NCT00437021 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain) NCT00998543 | Sanofi | — |
| Withdrawn | Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD) NCT00389103 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Terminated | Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive NCT00282581 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Completed | Safety and Immunogenicity of CJ-50300 NCT00336635 | Seoul National University Hospital | Phase 1 |
| Completed | A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallp NCT00316524 | Bavarian Nordic | Phase 2 |
| Completed | ACAM 3000 MVA at Harvard Medical School NCT00133575 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults NCT00258947 | Sanofi | Phase 2 |
| Completed | Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine NCT00466245 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Unknown | Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Vo NCT00103584 | VaxGen | Phase 1 / Phase 2 |
| Completed | VHA Clinicians and Bioterror Events: Interactive Web-based Learning NCT00123396 | US Department of Veterans Affairs | N/A |
| Completed | Combination Study With MVA BN and Dryvax NCT00082446 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Dryvax Dilution-Prev Vacc Adults NCT00032708 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adult NCT00079820 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Completed | Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects NCT00189969 | Bavarian Nordic | Phase 1 |
| Completed | Dressing Preparations for Smallpox NCT00063856 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox NCT00189956 | Bavarian Nordic | Phase 2 |
| Completed | Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults NCT00053482 | Emergent BioSolutions | Phase 2 |
| Completed | Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination NCT00053495 | Emergent BioSolutions | Phase 2 |
| Completed | Expanded Dryvax Dilution Study in Previously Vaccinated Adults NCT00050505 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Terminated | Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Va NCT00053508 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT NCT00038987 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine NCT00042094 | DynPort Vaccine Company LLC, A GDIT Company | Phase 1 |
| Completed | Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects NCT00189943 | Bavarian Nordic | Phase 1 |
| Completed | Human Immune Responses Smallpox NCT00068198 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Available | Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure NCT02080767 | U.S. Army Medical Research and Development Command | — |
| Completed | A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults NCT00026611 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | APSV in Vaccinia Naive Adults NCT00050518 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |